Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FS-1 in Drug-resistant Pulmonary Tuberculosis
NCT02607449Phase 3Completed
- Sponsor
- Scientific Center for Anti-Infectious Drugs
- Start
- Dec 2013
- Primary completion
- Aug 2020
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in pulmonary tuberculosis (TB) comparing FS-1 Arm with Placebo Arm (2 arms). Primary endpoints: Time to persistently negative sputum cultures at 18 months and Proportion of Patients with persistently negative sputum cultures (SCC) at 12 months. Started Dec 2013; status: completed.
02
Drugs
Efesovir
03
Conditions
pulmonary tuberculosis (TB)
Beyond the preview
Go deeper on NCT02607449.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02607449.